New medicine may reduce risk of Type 2 diabetes
Actos, a new medicine that treats adult onset diabetes may reduce the risk of Type 2 diabetes. AFP reports that the study followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.
Type 2 diabetes is caused by insufficient levels of insulin to keep blood glucose under control. Excessive levels of another hormone, glucagon, can also contribute to diabetes Type 2 by causing the liver to flood the body with stored glucose. Diabetes Type 2 doesn’t occur overnight, but slowly progresses for many years as a condition known as prediabetes.
The research findings showed that Actos, generically known as pioglitazone reduced the odds of developing Type 2 diabetes by 72% in people with prediabetes. Only 2.1% of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6% of those who took placebo.